Antitumour activity of cordycepin in mice. 2004

Noriko Yoshikawa, and Kazuki Nakamura, and Yu Yamaguchi, and Satomi Kagota, and Kazumasa Shinozuka, and Masaru Kunitomo
Department of Pharmacology, Faculty of Pharmaceutical Sciences, Mukpgawa Women's University, Nishinomiya, Japan.

1. The antitumour effect of orally administered cordycepin, a component isolated from water extracts of Cordyceps sinensis, was examined in mice inoculated with B16 melanoma (B16-BL6) cells. 2. B16-BL6 (1 x 10(6)) cells were inoculated subcutaneously into the right footpad of mice. At 2 weeks after the cell inoculation, the enlarged primary tumour lump was weighed. Cordycepin (0, 5 and 15 mg/kg per day) was administered orally to the mice for 2 weeks from the date of tumour inoculation. Cordycepin (15 mg/kg per day) significantly reduced by 36% the wet weight of the primary tumour lump compared to that of the untreated control mice, without any loss of bodyweight or systemic toxicity. 3. Cordycepin (15 mg/kg per day) administered orally for 2 weeks inhibited the tumour enlargement in the right thigh inoculated with B16-BL6 cells premixed with extracellular matrix (Matrigel). 4. These results indicate that orally administered cordycepin inhibits melanoma cell growth in mice with no adverse effects.

UI MeSH Term Description Entries
D008546 Melanoma, Experimental Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA. B16 Melanoma,Melanoma, B16,Melanoma, Cloudman S91,Melanoma, Harding-Passey,Experimental Melanoma,Experimental Melanomas,Harding Passey Melanoma,Melanomas, Experimental,B16 Melanomas,Cloudman S91 Melanoma,Harding-Passey Melanoma,Melanoma, Harding Passey,Melanomas, B16,S91 Melanoma, Cloudman
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D003839 Deoxyadenosines Adenosine molecules which can be substituted in any position, but are lacking one hydroxyl group in the ribose part of the molecule. Adenine Deoxyribonucleosides,Adenylyldeoxyribonucleosides,Deoxyadenosine Derivatives,Deoxyribonucleosides, Adenine,Derivatives, Deoxyadenosine
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D012878 Skin Neoplasms Tumors or cancer of the SKIN. Cancer of Skin,Skin Cancer,Cancer of the Skin,Neoplasms, Skin,Cancer, Skin,Cancers, Skin,Neoplasm, Skin,Skin Cancers,Skin Neoplasm
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines

Related Publications

Noriko Yoshikawa, and Kazuki Nakamura, and Yu Yamaguchi, and Satomi Kagota, and Kazumasa Shinozuka, and Masaru Kunitomo
June 1982, British journal of cancer,
Noriko Yoshikawa, and Kazuki Nakamura, and Yu Yamaguchi, and Satomi Kagota, and Kazumasa Shinozuka, and Masaru Kunitomo
January 1995, European journal of cancer (Oxford, England : 1990),
Noriko Yoshikawa, and Kazuki Nakamura, and Yu Yamaguchi, and Satomi Kagota, and Kazumasa Shinozuka, and Masaru Kunitomo
May 2012, International journal of pharmaceutics,
Noriko Yoshikawa, and Kazuki Nakamura, and Yu Yamaguchi, and Satomi Kagota, and Kazumasa Shinozuka, and Masaru Kunitomo
January 2012, Natural product research,
Noriko Yoshikawa, and Kazuki Nakamura, and Yu Yamaguchi, and Satomi Kagota, and Kazumasa Shinozuka, and Masaru Kunitomo
May 1985, British journal of cancer,
Noriko Yoshikawa, and Kazuki Nakamura, and Yu Yamaguchi, and Satomi Kagota, and Kazumasa Shinozuka, and Masaru Kunitomo
January 1972, Medical microbiology and immunology,
Noriko Yoshikawa, and Kazuki Nakamura, and Yu Yamaguchi, and Satomi Kagota, and Kazumasa Shinozuka, and Masaru Kunitomo
June 1998, Antimicrobial agents and chemotherapy,
Noriko Yoshikawa, and Kazuki Nakamura, and Yu Yamaguchi, and Satomi Kagota, and Kazumasa Shinozuka, and Masaru Kunitomo
April 1976, British journal of cancer,
Noriko Yoshikawa, and Kazuki Nakamura, and Yu Yamaguchi, and Satomi Kagota, and Kazumasa Shinozuka, and Masaru Kunitomo
February 1974, European journal of cancer,
Noriko Yoshikawa, and Kazuki Nakamura, and Yu Yamaguchi, and Satomi Kagota, and Kazumasa Shinozuka, and Masaru Kunitomo
January 2010, Zeitschrift fur Naturforschung. C, Journal of biosciences,
Copied contents to your clipboard!